Galapagos Unlocks scalability potential of POC CAR-Ts with BCA US collaboration
Galapagos announced a collaboration with Blood Centers of America (BCA), gaining access to BCA's network of >50 sites in the US for the decentralised manufacturing (POC) of Galapagos' CAR-T cell therapies (financial details not disclosed). We believe this collaboration could unlock significant manufacturing capacity for Galapagos in the US, and our back of the envelope calculation points to a capacity of 8K CAR-Ts per year with just 4 Cocoon's in each site – this comes close to Gilead's 2024 global capacity of approx. 10K CAR-Ts. We reiterate our TP of € 50, but view this agreement as a big step towards demonstrating the scalability of Galapagos' decentralised manufacturing model, and as such, we upgrade the company to a BUY (from ACCUMULATE).Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on its proprietary drug target discovery platform has delivered a pipeline that consists of three Phase 2, three Phase 1, five pre-clinical, and 20 discovery programs in inflammation, cystic fibrosis, or CF, osteoarthritis, and other indications. Co.'s highly flexible platform offers applicability across a broad set of therapeutic areas. Co.'s programs include filgotinib, GLPG1837, GLPG1690, GLPG2222, GLPG1972.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.